Get the Stockscreener App
7.418
0.82%
0.058
Arcturus Therapeutics Holdings Inc stock is traded at $7.418, with a volume of 187.12K.
It is up +0.82% in the last 24 hours and up +20.45% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$7.36
Open:
$7.4
24h Volume:
187.12K
Relative Volume:
0.17
Market Cap:
$210.55M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-6.3948
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
+4.51%
1M Performance:
+20.45%
6M Performance:
-50.33%
1Y Performance:
-55.00%
1-Day Range:
$7.3303
$7.59
1-Week Range:
$7.00
$7.89
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.41 | 209.13M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Roth Mkm - MarketBeat
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating By Investing.com - Investing.com India
Stifel Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $20 - 富途资讯
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating - Investing.com
Arcturus wins FDA fast track status for influenza vaccine - MSN
Price-Driven Insight from (ARCT) for Rule-Based Strategy - Stock Traders Daily
Market Review: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Valuation Update & Fast Moving Market Watchlists - baoquankhu1.vn
Aug EndMonth: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
FEDERATED HERMES, INC. Reduces Stake in Arcturus Therapeutics Ho - GuruFocus
Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility? - simplywall.st
Aug EndMonth: Should I hold or sell Arcturus Therapeutics Holdings Inc stock in 2025July 2025 Update & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Arcturus Therapeutics Holdings (ARCT) Valuation Check As J.P. Morgan Healthcare Conference Presentation Nears - Yahoo Finance
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference - MarketBeat
ARCT: Advancing mRNA therapies for CF and OTC with strong data, regulatory focus, and solid funding - TradingView
Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy? - Yahoo Finance
Ag Plus, Inc. - Ag Plus, Inc.
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 - Yahoo Finance
Will Arcturus Therapeutics Holdings Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Driven Stock Movement Reports - ulpravda.ru
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - Улправда
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
Citigroup Lowers Price Target for ARCT, Maintains Neutral Rating - GuruFocus
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics (NASDAQ:ARCT) Price Target Cut to $7.00 by Analysts at Citigroup - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - MarketScreener
MHRA approves Kostaive mRNA COVID-19 vaccine - The Pharma Letter
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arcturus Therapeutics Holdings files for mixed shelf of up to $500 millionSEC filing - MarketScreener
Arcturus Therapeutics Files $500 Million Mixed Shelf - MarketScreener
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics (ARCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Unveiling A 446% Potential Upside - directorstalkinterviews.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will Arcturus Therapeutics Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & Risk Controlled Daily Trade Plans - Улправда
How strong is Arcturus Therapeutics Holdings Inc. stock balance sheetMarket Activity Report & Weekly Watchlist of Top Performers - Улправда
How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataTrade Risk Assessment & Weekly High Return Stock Forecasts - Улправда
Why Arcturus Therapeutics Holdings Inc. stock could outperform in 2025Weekly Market Report & Daily Momentum Trading Reports - DonanımHaber
How supply chain issues affect Arcturus Therapeutics Holdings Inc. stockWeekly Trend Recap & AI Enhanced Market Trend Forecasts - DonanımHaber
Arcturus Therapeutics Holdings Inc. Announces Management Changes - marketscreener.com
Arcturus Therapeutics CFO Andy Sassine to leave company - marketscreener.com
Arcturus Therapeutics announces CFO transition and interim appointment By Investing.com - Investing.com Australia
Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks
Arcturus Therapeutics announces CFO departure and replacement - MSN
Arcturus Therapeutics announces CFO transition and interim appointment - Investing.com
Arcturus Therapeutics Announces CFO Departure and Interim Appointment - TradingView — Track All Markets
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):